Core Viewpoint - Orange County Bancorp, Inc. has launched an underwritten public offering of its common stock to support general corporate purposes, including investments in the Bank, regulatory capital, liquidity, and potential strategic acquisitions [1][2]. Group 1: Offering Details - The Company expects to grant underwriters a 30-day option to purchase additional shares of its common stock [1]. - The net proceeds from the offering will be used for general corporate purposes, which may include investments in the Bank, augmenting regulatory capital and liquidity, and potential strategic acquisitions [2]. Group 2: Regulatory Filings - The Company has filed a shelf registration statement and a preliminary prospectus supplement with the SEC for the offering [3]. - Investors are encouraged to read the preliminary prospectus supplement and accompanying prospectus for complete information about the Company and the offering [3]. Group 3: Company Background - Orange County Bancorp, Inc. is the parent company of Orange Bank & Trust Company and Hudson Valley Investment Advisors, Inc., with total assets of approximately $2.6 billion [5]. - Orange Bank & Trust Company has a history of over 125 years, focusing on community and business clientele [5].

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in controlling chronic cough [5] Public Offering Details - Trevi Therapeutics has initiated an underwritten public offering of $100,000,000 of its common stock, with an additional option for underwriters to purchase up to $15,000,000 more [1] - The offering is being managed by Morgan Stanley, Leerink Partners, Stifel, and Cantor as joint book-running managers [2] - The shares are offered under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3] Offering Conditions - The completion of the offering is subject to market and other conditions, with no assurance on the timing or terms of the offering [2] - A preliminary prospectus supplement detailing the terms of the offering is expected to be filed with the SEC [3]

Core Viewpoint - Femasys Inc. plans to conduct an underwritten public offering of its common stock, with an additional 30-day option for underwriters to purchase up to 15% more shares, alongside a concurrent private placement involving existing institutional stockholders and certain directors and officers [1][2]. Group 1: Offering Details - The public offering and private placement are subject to market conditions, with no assurance on completion timing or terms [2]. - Jones is the sole book-running manager for the public offering and placement agent for the private placement [3]. - The net proceeds from the offerings will be used for commercial expansion, product development, general corporate purposes, capital expenditures, and working capital [3]. Group 2: Regulatory Information - The securities are being offered under a Registration Statement on Form S-3, previously filed and declared effective by the SEC [4]. - The private placement will rely on an exemption from registration under the Securities Act, meaning the securities may not be sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - Femasys Inc. focuses on women's health, developing minimally invasive, in-office technologies for reproductive health, including products like FemBloc for permanent birth control and FemaSeed for infertility [6]. - Current marketed products include FemVue for fallopian tube assessment and FemCath, an intrauterine catheter for selective evaluation [6].

Core Viewpoint - Immunic, Inc. has initiated an underwritten public offering of various warrants to purchase shares of common stock, aimed at funding clinical trials and operations for its pipeline of therapies targeting chronic inflammatory and autoimmune diseases [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants, Series A warrants expiring on December 31, 2025, and Series B warrants expiring five years after issuance [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. - Leerink Partners is acting as the sole bookrunner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, operations, and other general corporate purposes [2]. Group 3: Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [5]. - The lead program, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [5]. - Vidofludimus calcium has shown therapeutic activity in earlier phase 2 trials and works as a first-in-class nuclear receptor related 1 (Nurr1) activator [5]. - Other candidates include IMU-856, targeting gastrointestinal diseases, and IMU-381, currently in preclinical testing [5].

Core Viewpoint - GDS Holdings Limited is initiating multiple offerings, including a public offering of American Depositary Shares (ADSs) and a private offering of convertible senior notes, to raise capital for general corporate purposes and refinancing existing debt [1][2][3]. Group 1: Primary ADSs Offering - The company plans to offer 5,200,000 ADSs, each representing eight Class A ordinary shares, with an underwriters' option for an additional 780,000 ADSs [1]. - The net proceeds from the Primary ADSs Offering will be used for general corporate purposes, working capital needs, and refinancing existing indebtedness, including potential repurchases of convertible bonds due in 2029 [2]. Group 2: Notes Offering - GDS Holdings is also proposing a private offering of convertible senior notes totaling US$450 million, due in 2032, with an option for initial purchasers to buy an additional US$50 million [3]. - This offering is targeted at qualified institutional buyers under Rule 144A of the Securities Act [3]. Group 3: Delta Placement of Borrowed ADSs - The company will conduct a separate registered public offering of borrowed ADSs to facilitate derivative transactions for holders of the notes [4]. - The proceeds from the sale of the borrowed ADSs will go to the ADS Borrower, while GDS will receive a nominal lending fee [4]. Group 4: Underwriters and Advisors - J.P. Morgan, BofA Securities, Morgan Stanley, and UBS Investment Bank are acting as joint book-running managers for the Primary ADSs Offering, with China Galaxy International and Guotai Junan International serving as financial advisors [6]. Group 5: Company Overview - GDS Holdings Limited is a leading developer and operator of high-performance data centers in China, strategically located in major economic hubs [9]. - The company offers co-location and value-added services, including managed hybrid cloud services, and has a diverse customer base, including hyperscale cloud service providers and large internet companies [9].

Core Viewpoint - Outlook Therapeutics, Inc. has announced a public offering of 9,285,714 shares of common stock at a price of $1.40 per share, along with warrants to purchase an additional 18,571,428 shares, aiming to raise approximately $13.0 million in gross proceeds [1][2]. Group 1: Offering Details - The public offering includes common stock sold in combination with warrants, where each share sold comes with a warrant to purchase two additional shares at an exercise price of $1.40 [1]. - The offering is expected to close on May 27, 2025, pending customary closing conditions [1]. - BTIG, LLC is acting as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [2]. Group 3: Company Overview - Outlook Therapeutics focuses on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), aimed at enhancing the standard of care for retinal diseases [5]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for treating wet age-related macular degeneration (wet AMD) [5]. - The company plans to initiate the commercial launch of LYTENAVA™ in the EU and the UK in the second quarter of 2025, while the product remains investigational in the United States [5].

Core Viewpoint - Elbit Systems Ltd. has announced a public offering of 1,365,450 ordinary shares priced at $375 per share, with gross proceeds expected to be approximately $512 million before deductions [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 204,817 shares at the public offering price [1]. - The offering is expected to close on May 23, 2025, subject to customary closing conditions [1]. - The shares will be listed for trading on the Nasdaq Global Select Market [1]. Group 2: Financial Information - The gross proceeds from the offering are anticipated to be around $512 million, assuming no exercise of the underwriters' option [2]. - Elbit Systems plans to use the net proceeds for general corporate purposes [2]. Group 3: Underwriters - BofA Securities, J.P. Morgan, Jefferies, and Morgan Stanley are acting as joint book-running managers for the offering [3]. - Barak Capital Underwriting is serving as a placement agent for the underwriters in Israel [3]. Group 4: Company Overview - Elbit Systems is a leading global defense technology company, employing approximately 20,000 people across five continents [6][7]. - The company reported revenues of $1.9 billion for the three months ended March 31, 2025, with an order backlog of $23.1 billion as of that date [7].

Core Viewpoint - Elbit Systems Ltd. announced a public offering of 1,365,450 ordinary shares, all of which will be sold by the company, with a potential additional 15% option for underwriters [1][2][3] Group 1: Offering Details - The offering is made under an effective shelf registration statement on Form F-3 filed with the SEC on May 21, 2025, which became effective immediately [3] - The net proceeds from the offering will be used for general corporate purposes [1] - The ordinary shares are expected to be listed for trading on the Nasdaq Global Select Market [1] Group 2: Underwriters - BofA Securities, J.P. Morgan, Jefferies, and Morgan Stanley are engaged as joint book-running managers for the offering [2] Group 3: Company Overview - Elbit Systems is a leading global defense technology company, employing approximately 20,000 people across five continents [5][6] - The company reported revenues of $1.9 billion for the three months ended March 31, 2025, and has an order backlog of $23.1 billion as of that date [6]

Core Viewpoint - Senseonics Holdings, Inc. has initiated an underwritten public offering of its common stock, with a potential additional 15% of shares available for underwriters to purchase [1][2]. Group 1: Offering Details - The public offering is subject to market conditions and will be made under a "shelf" registration statement filed with the SEC [3]. - TD Cowen and Barclays are the joint book-running managers for the offering, with RBC Capital Markets and Lake Street acting as bookrunners [2]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on their website [3]. Group 2: Concurrent Private Placement - Abbott Laboratories has agreed to purchase up to $25 million of Senseonics' common stock in a separate private placement, contingent on the public offering's closing [4]. - The net proceeds from both the public offering and the concurrent private placement will be used to support the launch of Eversense 365, ongoing product development, and general corporate purposes [5]. Group 3: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management, with products like Eversense® 365 and Eversense® E3 [8]. - The company's CGM systems feature a small sensor that is implanted under the skin and communicates glucose data to a mobile app every 5 minutes [8].

Core Viewpoint - Silo Pharma, Inc. has announced a public offering of 3,333,338 shares of common stock at a price of $0.60 per share, along with associated warrants, aiming to raise approximately $2 million for general working capital purposes [1][2]. Group 1: Offering Details - The public offering includes 3,333,338 shares of common stock and two series of warrants (Series A-1 and Series A-2), each with an exercise price of $0.60 per share [1]. - The Series A-1 Warrants are exercisable upon issuance and will expire five years thereafter, while the Series A-2 Warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected to occur on or about May 16, 2025, subject to customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are expected to be approximately $2 million before deducting fees and expenses [2]. - The net proceeds will be used for general working capital purposes [2]. Group 3: Company Overview - Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [5]. - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]. - Research is conducted in collaboration with leading universities and laboratories [5].